The focus was on evaluating their ability to inhibit key digestive enzymes relevant to T2DM (α-amylase, α-glucosidase, sucrase, maltase) and obesity (pancreatic lipase). The gene discussed is PNLIP; the disease is type 2 diabetes mellitus.